the effect of immunomodulators on the immunogenicity of tnf-blocking therapeutic monoclonal antibodies a review的效果免疫调制剂对肿瘤坏死因子抑制剂中治疗性单克隆抗体的免疫原性审查.pdf

Krieckaert et al. Arthritis Research Therapy 2010, 12:217 /content/12/5/217 R E V I E W The ef ect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review 1 1 2 1 Charlotte Louise Maria Krieckaert* , Geertje Margret Bartelds , Willem Frederik Lems and Gerrit Jan Wolbink standard ization of the assays used to measure anti-TmAb Abstract anti bodies, and the timing of the measurements make Therapeutic monoclonal antibodies have immunogenicity a complex subject to investigate. Several revolutionized the treatment of various inl ammatory studies in various infl ammatory diseases demonstrate the diseases. Immunogenicity against these antibodies presence of anti-TmAb antibodies [1]. Table 1 gives an has been shown to be clinically important: it is overview of the reported frequency of anti-TmAb associated with shorter response duration because antibodies in infl ixi mab (antibodies to infl iximab, or of diminishing concentrations in the blood and with ATIs) and in adali mumab (anti-adalimumab antibodies, infusion reactions. Concomitant immunomodulators or AAAs) [2-22]. h e large variation in the percentages of in the form of methotrexate or azathioprine reduced anti-TmAb antibodies measured could be related to the the immunogenicity of therapeutic antibodies in diff erences in assays, duration of treatment, and the use rheumatoid arthritis, Cro